scPharmaceuticals (SCPH) to Release Quarterly Earnings on Tuesday

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect scPharmaceuticals to post earnings of ($0.28) per share and revenue of $11.63 million for the quarter.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. The firm had revenue of $12.15 million during the quarter, compared to analysts' expectations of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Stock Performance

NASDAQ SCPH traded down $0.09 during trading hours on Friday, reaching $2.42. The stock had a trading volume of 149,928 shares, compared to its average volume of 357,222. scPharmaceuticals has a 52-week low of $1.94 and a 52-week high of $5.65. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The stock has a market cap of $121.69 million, a P/E ratio of -1.27 and a beta of 0.17. The stock has a fifty day moving average of $2.64 and a 200 day moving average of $3.23.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Maxim Group decreased their target price on shares of scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of scPharmaceuticals in a report on Thursday, March 20th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.